Skip to main content
    K

    Kodiak Sciences Inc (KOD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $100.73
    -10.46 (-9.41%)

    Market Cap: $7.27B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Kodiak Sciences Inc (KOD) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Kodiak Sciences are Cytokinetics (CYTK), Krystal Biotech (KRYS) and Scholar Rock Holding (SRRK). By market cap, Kodiak Sciences ranks 8th of the 13 companies on this page; Apogee Therapeutics, Inc. Common Stock (APGE) is the largest at $10.22B.

    Peer Comparison

    KOD's ROIC of -1481.8% is below the peer median of -66.0%, and its revenue growth of 0.0% is below the median of 15.1%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Kodiak Sciences (KOD)$7.27BN/AN/A0.0%-1481.8%0.0%0.00%
    Cytokinetics Inc (CYTK)$7.82BN/A65.3x0.0%-66.0%2357.0%0.00%
    Krystal Biotech Inc (KRYS)$9.05B40.4x18.8x47.9%N/A30.2%0.00%
    Scholar Rock Holding Corp (SRRK)$5.27BN/AN/A0.0%-89.0%-100.0%0.00%
    Protagonist Therapeutics Inc (PTGX)$8.55B27.7x15.8x62.0%N/A5724.0%0.00%
    Xenon Pharmaceuticals Inc (XENE)$3.98BN/AN/A0.0%N/A-100.0%0.00%
    Abivax SA American Depositary Shares (ABVX)$7.67BN/AN/A0.0%-159.6%-6.8%0.00%
    Tarsus Pharmaceuticals Inc (TARS)$3.96BN/A5.4x-102.9%-393.6%63.9%0.00%
    Viking Therapeutics Inc (VKTX)$3.73BN/AN/A0.0%-61.0%0.0%0.00%
    Apogee Therapeutics, Inc. Common Stock (APGE)$10.22BN/AN/A0.0%N/A0.0%0.00%
    Axsome Therapeutics Inc (AXSM)$7.45BN/A8.6x-18.2%-48.1%51.9%0.00%
    Ionis Pharmaceuticals Inc (IONS)$4.84BN/A4.8x-56.9%-29.3%54.9%0.00%
    Spyre Therapeutics Inc. (SYRE)$9.88BN/AN/A0.0%N/A0.0%0.00%
    Peer median$7.56B34.1x12.2x0.0%-66.0%15.1%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Kodiak Sciences, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Cytokinetics Inc (CYTK)
    Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering...
    CYTK competitors
    Krystal Biotech Inc (KRYS)
    Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United...
    KRYS competitors
    Scholar Rock Holding Corp (SRRK)
    Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious...
    SRRK competitors
    Protagonist Therapeutics Inc (PTGX)
    Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical...
    PTGX competitors
    Xenon Pharmaceuticals Inc (XENE)
    Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders...
    XENE competitors
    Abivax SA American Depositary Shares (ABVX)
    Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections.
    ABVX competitors
    Tarsus Pharmaceuticals Inc (TARS)
    Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates...
    TARS competitors
    Viking Therapeutics Inc (VKTX)
    Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders.
    VKTX competitors
    Apogee Therapeutics, Inc. Common Stock (APGE)
    Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD)...
    Axsome Therapeutics Inc (AXSM)
    Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United...
    AXSM competitors
    Ionis Pharmaceuticals Inc (IONS)
    Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
    IONS competitors
    Spyre Therapeutics Inc. (SYRE)
    Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by...
    SYRE competitors

    Frequently Asked Questions About KOD

    Who are Kodiak Sciences' main competitors?

    The companies most similar to Kodiak Sciences include Cytokinetics (CYTK), Krystal Biotech (KRYS), Scholar Rock Holding (SRRK), Protagonist Therapeutics (PTGX) and Xenon Pharmaceuticals (XENE), listed from the closest match.

    Who is Kodiak Sciences' biggest competitor?

    Apogee Therapeutics, Inc. Common Stock (APGE) is the largest of the similar companies at $10.22B; Cytokinetics (CYTK) is the closest match by business profile, size, sector and industry.

    How does KOD stock compare with its competitors?

    KOD's net margin is 0.0% against a peer median of 0.0%.

    Which of Kodiak Sciences' competitors pays a higher dividend?

    Kodiak Sciences pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Kodiak Sciences bigger than its competitors?

    No. Kodiak Sciences is 8th by market cap among the 13 companies on this page; the largest is Apogee Therapeutics, Inc. Common Stock (APGE) at $10.22B.